PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition
Authors
Martin, LeenusCheng, Tzuling
James, Dominic I
Begum, Habiba
Smith, Kate M
Jordan, Allan M
Waddell, Ian D
Vaidya, Kedar
Fischer, Marcus
Yao, Bing
Drummond, Jason
Cleary, Leah
Martinez, Ruben
Sutton, James
Ravindran, Nandini
Joseph, James
Venetsanakos, Eleni
Dillon, Michael
Hager, Jeffrey H
Belmont, Lisa D
Affiliation
Ideaya Biosciences, Inc., South San Francisco, CAIssue Date
2018
Metadata
Show full item recordCitation
Martin L, Cheng T, James DI, Begum H, Smith KM, Jordan A, et al. Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition. Cancer Res. 2018;78(13):1943.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2018-1943Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2018-1943Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2018-1943